Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose dexamethasone for connective tissue disease–associated thrombocytopenia
ChiCTR2500107158Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dexamethasone in Thrombocytopenia, systemic lupus erythematosus (SLE), primary Sjögren's syndrome and 1 more, sponsored by Beijing Hospital. Primary endpoint: overall remission rate at 24 weeks. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
dexamethasone
03
Conditions
Thrombocytopeniasystemic lupus erythematosus (SLE)primary Sjögren's syndromeUndifferentiated Connective Tissue Disease (UCTD)
Beyond the preview
Go deeper on ChiCTR2500107158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107158.